Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)
Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Listed as NCT03359018, this PHASE2 trial focuses on Clinical Benefit Rate and Overall Survival and remains completed. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
May 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
- Peking University People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .